Biotheryx Inc. has entered into a research collaboration and license agreement with Incyte Corp. to discover and develop targeted protein degraders for novel oncology targets.

Absci Corp. and M2gen have entered into a partnership to create new cancer medicines. Absci’s generative artificial intelligence drug creation platform will leverage M2gen’s clinical and molecular data set, ORIEN Avatar, to accelerate the creation of therapeutics for a range of malignancies and patient profiles.

Calyx (Perceptive Informatics LLC) has entered into a strategic partnership with Ceretype Neuromedicine Inc., whose novel functional magnetic resonance imaging (fMRI) platform incorporates optimal image acquisition and advanced analytics to de-risk and accelerate the development of psychiatric and neurological therapies

Evergreen Discovery (Evergreen Theragnostics Inc.) and Orbit Discovery Ltd. have entered into a collaboration to identify specific cell-targeting peptides and advance the development of novel radiopharmaceuticals.

Immunoprecise Antibodies Ltd.'s Talem Therapeutics LLC subsidiary has entered into a research collaboration and exclusive option license agreement with Xyphos Biosciences Inc., a wholly owned subsidiary of Astellas Pharma Inc.

Gandeeva Therapeutics Inc. has entered into a research collaboration with Moderna Inc. to...

Kaken Pharmaceutical Co. Ltd. and Bitbiome Inc. have entered into an agreement to collaborate on the creation of new drugs targeting infectious diseases with unmet medical needs.